Consistently, compared with rGCLM-WT overexpression, rGCLM-Mut overexpression significantly inhibited the transcriptional activity of NF-κB/p65 (Fig. 4e), reduced the expression of representative NF-κB/p65 downstream genes (Supplementary Fig. 4b), decreased the viability of CRC cells (Fig. 4f and Supplementary Fig. 4c), and increased the number of apoptotic cells in either the absence or presence of oxaliplatin treatment (Fig. 4g and Supplementary Fig. 4d). This evidence concerns the gene NFKB1 and colorectal carcinoma.